Merus to Present at the Jefferies 2018 Healthcare Conference
UTRECHT, The Netherlands, May 31, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics® ), today announced that Hui Liu, Ph.D., Executive Vice President and Chief Business Officer, will present a company overview at the Jefferies 2018 Healthcare Conference on Thursday, June 7, 2018, at 3:00 p.m. ET.
A live webcast of the presentation will be available on the Investors page of the Company's website, http://www.merus.nl. An archived presentation will be available for 90 days.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics® . Biclonics® , which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. Merus' most advanced bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 2 combination trial in two metastatic breast cancer populations. MCLA-128 is also being evaluated in a Phase 1/2 clinical trial in gastric, ovarian, endometrial and non-small cell lung cancers. Additional pipeline programs include MCLA-117, which is currently being studied in a Phase 1 clinical trial in patients with acute myeloid leukemia, and MCLA-158, a Biclonics® being studied in a Phase 1 clinical trial in patients with solid tumors with an initial focus on metastatic colorectal cancer. Through its collaboration with Incyte Corporation, Merus is also developing a preclinical bispecific antibody designed to bind to PD-L1 and a non-disclosed second immunomodulatory target. For additional information, please visit Merus' website, www.merus.nl .
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Globenewswire
Appian Corporation19.6.2019 16:30:17 CEST | Pressemeddelelse
Appian Named A Leader in Digital Process Automation for Deep Deployments Report by Independent Research Firm
HIPAAT International18.6.2019 18:35:41 CEST | Pressemeddelelse
Data Privacy and Governance Solution Now Cloud-based
Corel18.6.2019 15:03:12 CEST | Pressemeddelelse
Parallels® Remote Application Server 17 Brings Simplicity and Scalability to End User Computing for Microsoft RDS, VDI and DaaS with Time-Saving Innovations
Abeona Therapeutics Inc.18.6.2019 14:31:26 CEST | Pressemeddelelse
Abeona Therapeutics Receives FDA Fast Track Designation for ABO-202 AAV9 Gene Therapy in CLN1 Disease
Bombardier Transportation18.6.2019 10:43:15 CEST | Pressemeddelelse
Bombardier to supply 30 additional FLEXITY Trams to Brussels Transportation Company
HAProxy Technologies17.6.2019 14:02:05 CEST | Pressemeddelelse
Major HAProxy Releases Increase Support for Cloud-Native and Containerized Application Architectures
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum